News from viracyte, llc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 22, 2017, 09:00 ET ViraCyte Announces Positive Phase 2 Trial Results

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, today announced publication of...

Jul 18, 2017, 09:00 ET ViraCyte Enters Exclusive License Agreement with Baylor College of Medicine for T Cell Immunotherapies Targeting Viruses

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, today announced that it has...

Jul 11, 2017, 09:00 ET ViraCyte Completes Phase 1 Clinical Trial of Viralym-C

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, today announced the successful...

Jul 05, 2017, 09:00 ET ViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell Immunotherapies

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, today announced that it has been ...

Jan 24, 2017, 08:00 ET ViraCyte Receives Orphan Drug Designation for Viralym-C

ViraCyte, LLC, a clinical stage biopharmaceutical company developing immunotherapies for life threatening infections, announced today that the U.S....

Jan 10, 2017, 09:00 ET ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C

ViraCyte, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Viralym-C, ViraCyte's T cell...

Dec 01, 2016, 09:00 ET ViraCyte Announces Oral Presentations on Clinical Trial Results at the 58th American Society of Hematology Annual Meeting

ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today ...

Nov 29, 2016, 09:00 ET ViraCyte Appoints Dr. Brett Giroir as President and Chief Executive Officer

ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today ...